Devices industry welcomes far-reaching NICE (UK National Institute for Clinical Excellence) review
This article was originally published in Clinica
Executive Summary
The UK medical systems industry has welcomed a parliamentary report on the first three years of operation of the National Institute for Clinical Excellence (NICE). The review is, however, also being seen by the wider healthcare industry as an important part of a necessary broader reform of healthcare policy, particularly with regard to prioritisation.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.